Pluristem Therapeutics Inc. has signed a memorandum of understanding (MOU) for a collaboration with Fukushima Medical University, Fukushima Global Medical Science Center. The purpose of the collaboration is to develop Pluristem’s PLX-R18 cells for the treatment of acute radiation syndrome (ARS), and for morbidities following radiotherapy in cancer patients. ARS is caused by exposure to dangerously high levels of radiation, such as could occur in a nuclear catastrophe, and incorporates p...